Common use of Immediate Termination of Trial by Sponsor Clause in Contracts

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Provider and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug. (3) Immediate Termination of Trial by Provider and/or Principal Investigator. Provider and/or Principal Investigator reserves the right to terminate the Trial immediately upon notification to Sponsor if requested to do so by the responsible IEC or if such termination is required to protect the health of Trial Subjects.

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Provider Institution and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug. (3) Immediate Termination of Trial by Provider Institution and/or Principal Investigator. Provider Institution and/or Principal Investigator reserves reserve the right to terminate the Trial immediately upon notification to Sponsor and/or CRO if requested to do so by the responsible IEC and/or RA or if such termination is required to protect the health of Trial Subjects.

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Provider and Principal Investigator for causes that include failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug. (3) Immediate Termination of Trial by Provider and/or Principal Investigator. Provider and/or Principal Investigator reserves reserve the right to terminate the Trial immediately upon notification to Sponsor and/or CRO if requested to do so by the responsible IEC and/or RA or if such termination is required to protect the health of Trial Subjects.

Immediate Termination of Trial by Sponsor. Sponsor further reserves the right to terminate the Trial immediately upon written notification to Provider Institution and Principal Investigator for causes that include but are not limited to failure to enroll Trial Subjects at a rate sufficient to achieve Trial performance goals; material unauthorized deviations from the Protocol or reporting requirements; circumstances that in Sponsor’s opinion pose risks to the health or wellbeing of Trial Subjects; or regulatory agency actions relating to the Trial or the Sponsor Drug or Comparator Drug. (3) Immediate Termination of Trial by Provider Institution and/or Principal Investigator. Provider Institution and/or Principal Investigator reserves reserve the right to terminate the Trial immediately upon notification to Sponsor and/or CRO if requested to do so by the responsible IEC and/or RA or if such termination is required to protect the health of Trial Subjects.